A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis

被引:56
作者
Etheridge, S. Leah [1 ]
Cosgrove, Megan E. [1 ]
Sangkhae, Veena [1 ]
Corbo, Lana M. [1 ]
Roh, Michelle E. [1 ]
Seeliger, Markus A. [2 ]
Chan, Edward L. [3 ]
Hitchcock, Ian S. [1 ]
机构
[1] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA
[3] SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA
关键词
TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; V617F; DOMAIN; TET2; PHOSPHORYLATION; PROGRESSION; JAK2V617F; EXON-12; PV;
D O I
10.1182/blood-2012-12-473777
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Along with the most common mutation, JAK2V(617)F, several other acquired JAK2 mutations have now been shown to contribute to the pathogenesis of myeloproliferative neoplasms (MPNs). However, here we describe for the first time a germline mutation that leads to familial thrombocytosis that involves a residue other than Val(617). The novel mutation JAK2R(564)Q, identified in a family with autosomal dominant essential thrombocythemia, increased cell growth resulting from suppression of apoptosis in Ba/F3-MPL cells. Although JAK2R(564)Q and JAK2V(617)F have similar levels of increased kinase activity, the growth-promoting effects of JAK2R(564)Q are much milder than those of JAK2V(617)F because of at least 2 counter regulatory mechanisms. Whereas JAK2V(617)F can escape regulation by the suppressor of cytokine signaling 3 and p27/Kip1, JAK2R(564)Q-expressing cells cannot. Moreover, JAK2R(564)Q-expressing cells are much more sensitive to the JAK inhibitor, ruxolitinib, than JAK2V(617)F-expressers, suggesting that lower doses of this drug may be effective in treating patients with MPNs associated with alternative JAK2 mutations, allowing many undesirable adverse effects to be avoided. This work provides a greater understanding of the cellular effects of a non-JAK2V(617)F, MPN-associated JAK2 mutation; provides insights into new treatment strategies for such patients; and describes the first case of familial thrombosis caused by a JAK2 residue other than Val(617).
引用
收藏
页码:1059 / 1068
页数:10
相关论文
共 38 条
[31]   Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms [J].
Quintas-Cardama, Alfonso ;
Vaddi, Kris ;
Liu, Phillip ;
Manshouri, Taghi ;
Li, Jun ;
Scherle, Peggy A. ;
Caulder, Eian ;
Wen, Xiaoming ;
Li, Yanlong ;
Waeltz, Paul ;
Rupar, Mark ;
Burn, Timothy ;
Lo, Yvonne ;
Kelley, Jennifer ;
Covington, Maryanne ;
Shepard, Stacey ;
Rodgers, James D. ;
Haley, Patrick ;
Kantarjian, Hagop ;
Fridman, Jordan S. ;
Verstovsek, Srdan .
BLOOD, 2010, 115 (15) :3109-3117
[32]   Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms [J].
Schaub, Franz X. ;
Looser, Renate ;
Li, Sai ;
Hui Hao-Shen ;
Lehmann, Thomas ;
Tichelli, Andre ;
Skoda, Radek C. .
BLOOD, 2010, 115 (10) :2003-2007
[33]   JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [J].
Scott, Linda M. ;
Tong, Wei ;
Levine, Ross L. ;
Scott, Mike A. ;
Beer, Philip A. ;
Stratton, Michael R. ;
Futreal, P. Andrew ;
Erber, Wendy N. ;
McMullin, Mary Frances ;
Harrison, Claire N. ;
Warren, Alan J. ;
Gilliland, D. Gary ;
Lodish, Harvey F. ;
Green, Anthony R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (05) :459-468
[34]   Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis [J].
Teofili, Luciana ;
Giona, Fiorina ;
Torti, Lorenza ;
Cenci, Tonia ;
Ricerca, Bianca Maria ;
Rumi, Carlo ;
Nunes, Vittorio ;
Foa, Robin ;
Leone, Giuseppe ;
Martini, Maurizio ;
Larocca, Luigi Maria .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (01) :65-70
[35]   Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice [J].
Tiedt, Ralph ;
Hao-Shen, Hui ;
Sobas, Marta A. ;
Looser, Renate ;
Dirnhofer, Stephan ;
Schwaller, Juerg ;
Skoda, Radek C. .
BLOOD, 2008, 111 (08) :3931-3940
[36]  
Verstovsek Srdan, 2009, Hematology Am Soc Hematol Educ Program, P636, DOI 10.1182/asheducation-2009.1.636
[37]   Activated Jak2 with the V617F point mutation promotes G1/S phase transition [J].
Walz, Christoph ;
Crowley, Brian J. ;
Hudon, Heidi E. ;
Gramlich, Jessica L. ;
Neuberg, Donna S. ;
Podar, Klaus ;
Griffin, James D. ;
Sattler, Martin .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (26) :18177-18183
[38]   A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation [J].
Zhao, Lequn ;
Dong, Hongyun ;
Zhang, Cheng Cheng ;
Kinch, Lisa ;
Osawa, Mitsujiro ;
Iacovino, Michelina ;
Grishin, Nikolai V. ;
Kyba, Michael ;
Huang, Lily Jun-shen .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (39) :26988-26998